Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia.
Nygren PJ, Bouhlal JOV, Jokinen E, Forstén S, Laajala E, Dias DAA, Adnan Awad S, Ianevski A, Klievink J, Lähteenmäki H, Kuusanmäki H, Myllymäki M, Kasanen T, Saeed K, Lee DA, Flagship I, Hjorth-Hansen H, Aittokallio T, Dufva O, Mustjoki S. Nygren PJ, et al. Among authors: kuusanmaki h. Blood. 2025 Jan 10:blood.2024025286. doi: 10.1182/blood.2024025286. Online ahead of print. Blood. 2025. PMID: 39792962
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma.
Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner L, Valent P, Aittokallio T, Herling M, Mustjoki S, Gunning PT, Moriggl R. Pölöske D, et al. Among authors: kuusanmaki h. Hemasphere. 2024 Nov 28;8(12):e70001. doi: 10.1002/hem3.70001. eCollection 2024 Dec. Hemasphere. 2024. PMID: 39619245 Free PMC article.
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.
Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, Ruokoranta T, Kuusanmäki H, Ikonen N, Sergeev P, Vähä-Koskela M, Giri AK, Vähärautio A, Kontro M, Porkka K, Pitkänen E, Heckman CA, Wennerberg K, Aittokallio T. Ianevski A, et al. Among authors: kuusanmaki h. Nat Commun. 2024 Oct 3;15(1):8579. doi: 10.1038/s41467-024-52980-5. Nat Commun. 2024. PMID: 39362905 Free PMC article.
Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.
Kytölä S, Vänttinen IM, Ruokoranta T, Partanen A, Holopainen A, Saad J, Kuusisto MEL, Koskela S, Räty RK, Itälä-Remes M, Västrik I, Suvela M, Parsons AO, Porkka K, Wennerberg K, Heckman CA, Jalkanen T, Huttunen T, Ettala P MD, Rimpiläinen J, Siitonen T, Pyörälä M, Kuusanmäki H, Kontro M. Kytölä S, et al. Among authors: kuusanmaki h. Blood. 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968. Online ahead of print. Blood. 2024. PMID: 39357056
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses.
von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl R, Mazzeo P, Schmidt N, Koch R, Hallek M, Chebel A, Armisen D, Genestier L, Bachy E, Mishra A, Schrader A, Aittokallio T, Mustjoki S, Herling M. von Jan J, et al. Among authors: kuusanmaki h. Blood. 2024 Oct 10;144(15):1595-1610. doi: 10.1182/blood.2023022884. Blood. 2024. PMID: 38941598
Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window.
Satomaa T, Pynnönen H, Aitio O, Hiltunen JO, Pitkänen V, Lähteenmäki T, Kotiranta T, Heiskanen A, Hänninen AL, Niemelä R, Helin J, Kuusanmäki H, Vänttinen I, Rathod R, Nieminen AI, Yatkin E, Heckman CA, Kontro M, Saarinen J. Satomaa T, et al. Among authors: kuusanmaki h. Mol Cancer Ther. 2024 Aug 1;23(8):1073-1083. doi: 10.1158/1535-7163.MCT-23-0720. Mol Cancer Ther. 2024. PMID: 38561023
Standardized assays to monitor drug sensitivity in hematologic cancers.
Ayuda-Durán P, Hermansen JU, Giliberto M, Yin Y, Hanes R, Gordon S, Kuusanmäki H, Brodersen AM, Andersen AN, Taskén K, Wennerberg K, Enserink JM, Skånland SS. Ayuda-Durán P, et al. Among authors: kuusanmaki h. Cell Death Discov. 2023 Dec 1;9(1):435. doi: 10.1038/s41420-023-01722-5. Cell Death Discov. 2023. PMID: 38040674 Free PMC article.
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Pyörälä M, Rimpiläinen J, Siitonen T, Kontro M. Kuusanmäki H, et al. Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692. Haematologica. 2023. PMID: 36519325 Free PMC article.
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, Nygren P, Klievink J, Bouhlal J, Pölönen P, Zhang Q, Adnan-Awad S, Mancebo-Pérez C, Saad J, Miettinen J, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Heinäniemi M, Theilgaard-Mönch K, Wartiovaara-Kautto U, Keränen M, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S. Kuusanmäki H, et al. Blood. 2023 Mar 30;141(13):1610-1625. doi: 10.1182/blood.2021011094. Blood. 2023. PMID: 36508699 Free PMC article.
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, Kuusanmäki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Västrik I, Kivinen K, Saarela J, Räty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Malani D, et al. Among authors: kuusanmaki h. Cancer Discov. 2022 Feb;12(2):388-401. doi: 10.1158/2159-8290.CD-21-0410. Epub 2021 Nov 17. Cancer Discov. 2022. PMID: 34789538 Free PMC article.
31 results